American Society of Clinical Oncology 2011 CNS tumors update

Expert Rev Anticancer Ther. 2011 Oct;11(10):1495-7. doi: 10.1586/era.11.151.

Abstract

A number of important studies were presented at the CNS tumors section of the 2011 American Society of Clinical Oncology Annual Meeting. There was particular interest in RTOG 0525, a Phase III study of newly diagnosed glioblastoma treated with different schedules of temozolomide. Prognostic factors for response, survival and chemotherapy-related toxicity in primary CNS lymphoma from the German randomized Phase III trial in newly diagnosed primary CNS lymphoma were also presented.

Publication types

  • Congress

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Central Nervous System Neoplasms / drug therapy*
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Dacarbazine / administration & dosage
  • Dacarbazine / analogs & derivatives*
  • Glioblastoma / drug therapy*
  • Humans
  • Randomized Controlled Trials as Topic
  • Temozolomide

Substances

  • Antineoplastic Agents
  • Dacarbazine
  • Temozolomide